{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-017147","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.254649+00:00","generated_at":"2026-06-03T04:15:30.265240+00:00","sec_items":["1.01","2.01","2.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Daré Bioscience secures $22M non-dilutive royalty financing from XOMA for XACIATO and Phase 3 candidates","bullets":["XOMA paid $22M upfront for 100% of Daré's net XACIATO royalties and milestones (after deductions); Daré also sold minority interest in Ovaprene/Sildenafil future revenue.","After XOMA achieves pre-specified return, Daré receives 50% of each successive $22M received (upside-sharing).","Synthetic royalties: 4% on Ovaprene net sales, 2% on Sildenafil Cream net sales, decreasing to 2.5% and 1.25% after further return threshold.","Total royalty-based capital committed ($34M) includes previous UiE financing; Daré retains significant majority of future economics.","Proceeds to fund Phase 3 pivotal programs for Ovaprene (contraceptive) and Sildenafil Cream (female sexual arousal disorder)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-017147","json":"https://secwatch.observer/filing/0001493152-24-017147.json","markdown":"https://secwatch.observer/filing/0001493152-24-017147.md","text":"https://secwatch.observer/filing/0001493152-24-017147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224017147/0001493152-24-017147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224017147/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:15:30.265240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a37e40144520bd5cb290b5cdd4c95d5295229c5","claim":"Dare Bioscience, Inc. entered into Traditional Royalty Purchase Agreement with XOMA (US) LLC valued at $22.0 million (effective 2024-04-29).","evidence_excerpt":"On April 29, 2024, Daré Bioscience, Inc. (“Daré” or the “Company”) entered into a Traditional Royalty Purchase Agreement and a Synthetic Royalty Purchase Agreement (together, the “Agreements”) with XOMA (US) LLC (“XOMA”). In accordance with the Agreements, on April 29, 2024, XOMA paid $22.0 million to Daré","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224017147/0001493152-24-017147-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"XOMA (US) LLC"},{"label":"Value","value":"$22.0 million"},{"label":"Effective","value":"2024-04-29"}],"fact_type":"material_agreement"},{"claim_id":"ed9db288ecde3d55fc00ca6fd8795bfec8659e16","claim":"Dare Bioscience, Inc. entered into Synthetic Royalty Purchase Agreement with XOMA (US) LLC (effective 2024-04-29).","evidence_excerpt":"On April 29, 2024, Daré Bioscience, Inc. (“Daré” or the “Company”) entered into a Traditional Royalty Purchase Agreement and a Synthetic Royalty Purchase Agreement (together, the “Agreements”) with XOMA (US) LLC (“XOMA”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224017147/0001493152-24-017147-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"XOMA (US) LLC"},{"label":"Effective","value":"2024-04-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}